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Background & Aims. Assess the clinical utility of the Prati criteria and normal ALT (<40IU/L) in a cohort of patients with chronic
hepatitis B infection (CHB). Methods. Serology, radiology, and histology were obtained in 140 patients with CHB. Results.H B e A g +
group: 7 patients (7/56−12% HBeAg+ group) misclassiﬁed as “immunotolerant”, with HBV DNA > 6 log copies/ml and normal
ALT, who in fact had moderate/severe ﬁbrosis on liver biopsy. HBeAg− group: 10 patients with normal ALT and moderate/severe
ﬁbrosis on liver biopsy; 4 of these patients had >3 log copies/ml HBV DNA levels and 6 patients misclassiﬁed as “inactive carriers”
with negative HBV DNA levels normal ALT and moderate/severe ﬁbrosis (6/84−7% HBeAg− group). Two male HBeAg+ and three
male HBeAg− patients with ALT between 20 and 30 IU/L and moderate/severe ﬁbrosis on liver biopsy would have been further
mischaracterisedusingthePraticriteriafornormalALT.Ageandethnicgroupweremoreimportantpredictorsofmoderate/severe
ﬁbrosis in multivariate analysis. Conclusion. HBeAg status, age, ethnic origin with longitudinal assessment of LFTs and viral load
should be studied in patients with “normal ALT” at the upper end of normal range (ALT 20–40 IU/L) to appropriately classify
patients and identify patients for liver ﬁbrosis assessment to inform treatment decisions.
1.Introduction
An estimated 400 million people worldwide have chronic
hepatitis B virus infection, of whom 1 million people will
die each year from its complications [1, 2]. In the United
Kingdom, it is estimated that over 180,000 people are
infected, with the numbers increasing rapidly (http://www
.hepb.org.uk/).
In general, patients with chronic hepatitis B infection
have historically been stratiﬁed into 4 classic categories
according to the natural history of the infection [2, 3].
(1) Immune-tolerant phase: HBeAg positive with high
levels of viral replication (HBV DNA levels: >6l o g ) ,
normal ALT, without necroinﬂammation in the liver
and a low risk of progression to cirrhosis.
(2) Immune-active phase: HBeAg positive with high
levels of viral replication (HBV DNA levels: >6l o g ) ,
increased ALT, necroinﬂammation in the liver with a
high risk of progression to cirrhosis.
(3) Inactive HBV carrier state: these patients have under-
gone seroconversion to anti-HBe status. It is charac-
terised by very low/undetectable HBV DNA levels,
normal ALT, without necroinﬂammation on liver
histology and low risk of progression to cirrhosis.2 Hepatitis Research and Treatment
(4) HBeAg-negative chronic hepatitis B infection (pre-
core/basal core mutant disease) the development
of a pre-core/basal core mutant results in active
viral replication. These patients have detectable HBV
DNA levels (but traditionally lower than HBeAg-
positive patients), with ﬂuctuating levels of ALT,
necroinﬂammation in the liver, and a high risk of
progression to cirrhosis.
The European Association for the Study of the Liver
(EASL) and the American Association for the Study of Liver
Diseases (AASLD) have both recently published guidelines
on the management and treatment of chronic HBV [3–5].
Before embarking on a treatment algorithm, it is important
to identify the parameters that determine which patients
require treatment [6] .T h e s ep a r a m e t e r sa sr e c o m m e n d e d
by the Asian Paciﬁc Association for the Study of the Liver
(APASL), EASL, and AASLD include hepatitis serology,
HBV DNA levels, serum ALT, and liver histology. Recent
recognition of the important prognostic value of HBV
DNA levels is reﬂected in the removal of emphasis on liver
biopsy in the assessment of patients with chronic hepatitis
B infection [7]. Current guidelines recommend selection of
patients for liver biopsy based primarily on their ALT values.
Until recently a so-called “normal ALT” (ALT < 40IU/L)
was thought to exclude hepatic inﬂammation and signiﬁcant
liver ﬁbrosis. However, recent evidence in chronic hepatitis
C infection suggests that a normal ALT at the upper limit
of normal contains a signiﬁcant number of patients with
hepatic inﬂammation and liver ﬁbrosis on liver biopsy [8,
9]. This eﬀect has also been shown in other liver diseases
resulting in the development of the Prati criteria for normal
ALTinthelastdecade.ThePraticriteriafornormalALTisan
ALT < 30IU/L in men and ALT < 19IU/L in women [10, 11].
The aim of the study was to perform a cross-sectional
analysis of a population of patients with chronic hepatitis B
infectionusingserological,radiological,andhistologicaldata
to assess the clinical utility of a normal ALT (<40IU/L) and
the Prati criteria.
2. Method
2.1. Patient Selection. Adult patients with chronic HBV
infection (deﬁned as HBsAg-positive for greater than 6
months) were recruited from primary care, antenatal, or
sexual health clinics at a single centre at St Mary’s Hospital,
London, UK. The study was approved by the hospital ethics
committee, with a total of 140 treatment naive chronic HBV
patients recruited into the study between 2003 and 2008.
The patients were recruited prospectively in a consecutive
manner. The patients had the following assessment.
2.2. Clinical Assessment. A complete history and physical
examination was performed on all patients. Patients with a
high alcohol intake (>150grams/week) were excluded from
the study.
2.3.SerumAnalysis. Aserumsamplewasobtainedfromeach
patient at the initial study visit as part of the IRB protocol.
Laboratory investigations included routine CBC, serum elec-
trolytes, and liver biochemistry (ALT, AST, bilirubin, ALP,
GGT). Hepatitis B serology included HBsAg/Ab, HBeAg/
Ab, and HBcAb using standard assays. Serum HBV DNA
(copies/mL) was measured using ABBOTT real-time quan-
titative PCR and ABI PRISM.
2.4. Radiology Tests. All patients had a liver ultrasound scan.
The scans were reported by a consultant radiologist with
specialist expertise in liver radiology.
2.5. Liver Biopsy and Histopathology. The histological diag-
nosis was established using hematoxylin & eosin (H &
E) staining and Masson’s trichrome stains of formalin
ﬁxed paraﬃn-embedded liver tissue. Two specialist liver
histopathologists reviewed all the biopsy material and for-
mally allocated ﬁbrosis scores to each specimen based on a
modiﬁed Ishak scoring system. Patients with a ﬁbrosis stage
of 0–2 were designated as having mild disease, 3-4 mod-
erate disease, and 5-6 severe disease (6=cirrhosis). Necro-
inﬂammatory scores of 0–3 indicated mild inﬂammation
whilst a score > 3 was considered signiﬁcant inﬂammation.
2.6. Patient Cohorts and Study Design. A combination of
hepatitis serology, HBV DNA levels, serum ALT, and liver
histology was obtained in a total of 140 patients with chronic
hepatitis B infection: HBeAg+ (n = 56) and HBeAg− (n =
84). The serum analysis, radiology, and liver biopsy were all
performed within 3 months of each other, with a median
timedelayof23daysbetweenthecorrespondingtestsineach
patient. The data was collected prospectively and the analysis
performed retrospectively.
2.7. Statistical Analysis. Numerical data are expressed as
mean +/− standard deviation. The t-test was used to
compare paired data.
Regression analysis was performed using SPSS software.
Univariate analysis identiﬁed an association between ﬁbrosis
and a variety of patient variables. Multivariate analysis was
performed on factors found to be signiﬁcant (P< 0.05) on
univariate analysis, to identify predictors of ﬁbrosis, and P-
values were generated for each of the variables.
3. Results
There were a total of 140 patients recruited into the study,
with the demographics and characteristics of the patients
provided in Table 1. The prevalence of hepatic steatosis
on liver in USA was 8% (11 patients) in the study. All
these patients had an abnormal ALT (ALT > 40IU/L). In
addition, 5 of the 11 individuals with hepatic steatosis had
a serum ALT > X2 ULN (>80IU/L) and NASH on liver
biopsy (macrovesicular steatosis, ballooning degeneration,
and lobular inﬂammation) complicating the hepatitis B
infection.
The HBeAg+ patients (n = 56) and HBeAg− patients
(n = 84) were stratiﬁed according to serum ALT. In the
HBeAg+ cohort, all the ALT subgroups had high levelsHepatitis Research and Treatment 3
Table 1: Demographics and characteristics of the chronic Hepatitis
B infection cohort.
Variable Outcome
Total (n) 140
Age (years) 39.5 ± 13.4
Gender (male) 84 (60%)
e A gs t a t u s( + ’ v e ) 5 6( 4 0 % )
Ethnic origin (C, A, AC) 76 (54%), 45 (32%), 19 (14%)
Serum ALT (IU/L) 86.6 ±53
Platelet count Normal (245 ±23)
Serum bilirubin, INR, Albumin normal (15µm o l / L ) ,n o r m a l( 1 ) ,
normal (40g/L)
Liver biopsy length 3.4 ± 1.1cm
Necroinﬂammatory score (Ishak) 4.0 ± 2
Fibrosis score 2.8 ± 1.8
R e s u l t sa r ee x p r e s s e da sm e a n± standard deviation and percentages.
Ethnic origin (C: Caucasian; A: Asian; AC: Afro-Caribean).
of HBV DNA (>6 logcopies/mL) as would be expected
for HBeAg+ patients (Tables 2 and 3). In the HBeAg−
patients, there was a variation in HBV DNA levels within
the diﬀerent ALT subgroups, with the higher ALT group
X2 ULN (>80IU/L) consisting of more patients with high
HBV DNA levels, as a result of the emergence of precore
mutant disease (Table 3). As expected, in both HBeAg+ and
HBeAg− cohorts, the patients with high ALT levels had
higher necroinﬂammatory scores (P<0.05) and ﬁbrosis
scores (P<0.05) than patients in the lower ALT subgroups
(Tables 2 and 3).
The so-called “immunotolerant” patients in the HBeAg+
cohortandthe“inactivecarriers”intheHBeAg− cohort were
further scrutinized. In the HBeAg+ group, there were a total
of 25 patients with normal ALT (<40IU/L). There were 7
patients (7/56−12% of total HBeAg+ group) misclassiﬁed
as “immunotolerant”, with HBV DNA > 6 log copies/mL
and normal ALT, who in fact had moderate/severe ﬁbrosis
on liver biopsy (Table 2). Statistical analysis showed that an
abnormal ALT (ALT > 40IU/L) yielded a sensitivity of 72%
and speciﬁcity of only 58% as a predictor of moderate/severe
liver ﬁbrosis in the HBeAg+ group (Table 4).
In the HBeAg− group, there were a total of 29 patients
with normal ALT (<40IU/L). There were 10 patients with
normal ALT and moderate/severe ﬁbrosis on liver biopsy;
4 of these patients had >3 log copies/mL HBV DNA levels
and 6 patients were misclassiﬁed as “inactive carriers” with
negativeHBVDNAlevelsandnormalALT(6/84−7%oftotal
HBeAg− group) (Table 3). Statistical analysis showed that an
abnormal ALT (ALT > 40IU/L) yielded a sensitivity of 85%
and speciﬁcity of only 53% as a predictor of moderate/severe
liver ﬁbrosis in the HBeAg− group.
In total, 9% of patients in the study (13/140; 7eAg+
and 6 eAg−) with moderate/severe ﬁbrosis would have been
incorrectly classiﬁed as immune tolerant or inactive carriers
if liver biopsy had not been performed. Subgroup analysis of
malesinourstudywithALT20and30IU/Lisalsoimportant
in relation to the application of the Prati criteria for normal
ALT. There were two male (immunotolerant) HBeAg+ and
three male (inactive carrier) HBeAg− patients with ALT
between20and30IU/Landmoderate/severeﬁbrosisonliver
biopsy, who would have been mischaracterised as normal if
using the Prati criteria for normal ALT (ALT < 30IU/L in
men and ALT < 19IU/L in women).
It is noteworthy that two patients in the HBeAg+
cohort with normal ALT were cirrhotic and one patient
in the HBeAg− cohort had negative HBV DNA levels
(<3logcopies/mL), normal ALT and cirrhosis on liver
biopsy emphasising further the importance of appropriately
stratifying patients with upper limit normal serum ALT.
Regardless of ALT not being a good predictor of liver
ﬁbrosisinthisstudy,animportantadditionalﬁndingwasthe
ability of the inﬂammatory score on liver biopsy to correlate
well with the serum ALT. Hence patients with ALT < 20IU/L
had much lower NI scores than patients with ALT 20–30 or
above (Tables 2 and 3).
3.1. Risk Factorsand Correlation with Liver Fibrosis in Patients
with Normal ALT. Factors that determined moderate/severe
liver ﬁbrosis were sought in all the chronic HBV patients.
The eﬀects of age (>45), gender (male), ethnic group
(Asian/African), HBV DNA level (>6 logcopies/mL), serum
ALT level (ALT > 40), and necroinﬂammatory score (N.I.
> 3) at the time of liver biopsy were analysed in regression
analysis using SPSS software. In univariate analysis, there
was a signiﬁcant correlation with age, ethnic group, HBV
DNA levels, and necroinﬂammatory score (P<0.05). In
multivariate analysis, only patient age and ethnic group were
associated with moderate/severe liver ﬁbrosis (Table 3— P<
0.05).
4. Discussion
This chronic hepatitis B infection study was designed as a
cross-sectional study assessing serological, radiological, and
histological data as is frequently encountered in clinical
practise. The results of this study are important as they
show that classiﬁcation and stratiﬁcation of patients into
immunotolerant and inactive carriers can be diﬃcult with
a single blood test using hepatitis B serology, viral load,
and liver function tests. The study results show that a
single serum ALT alone can give a false impression and be
misleading when predicting advanced liver disease in a small
proportion of patients, even if using the Prati criteria for
normal ALT (ALT < 30IU/L in men and ALT < 19IU/L in
women). Given the large number of patients worldwide with
chronic hepatitis B infection (>400 million), the number of
patients missed will be signiﬁcant [12, 13].
The idea of a liver biopsy in all adult HBeAg+ and
HBeAg− patients with “normal ALT” at the upper end
of normal range (ALT 20–40IU/L) is a daunting prospect
for clinicians as it goes beyond the Prati criteria, and
liver biopsy has well-recognised complications as well as
cost implications. The limitations of liver biopsy include
sampling error, interobserver variability in reporting and the
smallbutsigniﬁcantmorbidityandmortalityassociatedwith4 Hepatitis Research and Treatment
Table 2: The characteristics of 56HBeAg+ patients stratiﬁed according to serum ALT.
ALT category Total number of
patients
HBV DNA
(copies/mL) NI Score Mild ﬁbrosis (no.
of patients)
Mod/Severe ﬁbrosis
(no. of patients)
<20 8 (>6L o g ) 1 ± 1.5 8 0
20–30 6 (>6L o g ) 2 . 4± 2.14 2
31–40 11 (>6L o g ) 3 . 7± 2.36 5
41–80 16 (>6L o g ) 4± 2.58 8
>80 15 (>6L o g ) 5± 2.55 1 0
R e s u l t sa r ee x p r e s s e da sm e a n± standard deviation.
Table 3: Shows the characteristics of 84HBeAg− patients stratiﬁed according to serum ALT.
ALT category Total number
of patients
HBV DNA
NI score (mean) Mild ﬁbrosis
(no. patients)
Mod/Severe
ﬁbrosis (no.
patients)
log ranges
copies/mL (no. patients)
<20 1
<3l o g 1
11 0 3 log–6 log 0
>6l o g 0
20–30 13
<3 log 12 3.0
10 3 3 log–6 log 1
±1
>6l o g 0
31–40 15
<3 log 12 3.5
87 3 log–6 log 3
±1.5
>6l o g 0
41–80 37
<3 log 18 3.8
14 23 3 log–6 log 11
±2.5
>6l o g 8
>80 18
<3l o g 5 5 . 5
61 2 3 log–6 log 3
±1.5
>6l o g 1 0
R e s u l t sa r ee x p r e s s e da sm e a n± standard deviation.
Table 4: Multivariate analysis of factors associated with moderate/severe liver ﬁbrosis in the chronic hepatitis B cohort.
Category Variable
Univariate analysis
signiﬁcant factors
(P<0.05)
Multivariate analysis
signiﬁcant factors
(P<0.05)
Age Years (>45) Yes (P<0.05) Yes (0.045)
Gender Male No No
Ethnic group Asian/Afro-Caribean Yes (P<0.05) Yes (0.02)
Viral load HBV DNA level (>6log) Y es(P<0.05) No
Serum ALT ALT (>40) No No
Hepatic inﬂammation Necroinﬂammatory
Score (N.I.>3) Yes (P<0.05) No
this invasive procedure [14, 15]. Hence a focused approach
using HBeAg status, age, ethnic origin with longitudinal
assessment of LFTs and viral load should be studied in
patientswith“normalALT”attheupperendofnormalrange
(ALT20–40IU/L)toappropriatelyclassifypatientsandselect
patients that require an assessment of liver ﬁbrosis to inform
treatment decisions. The liver ﬁbrosis assessment in selected
patients could utilise novel noninvasive technologies, which
have the potential to identify liver ﬁbrosis in patients with
chronic hepatitis B infection. Serum markers of liver ﬁbrosis
and transient elastography could be performed in selected
patients with “normal ALT” at the upper end of normal
range (ALT 20–40IU/L), to identify the small proportion
of patients with moderate/severe liver ﬁbrosis [16–19]. AnHepatitis Research and Treatment 5
abnormal result could trigger a liver biopsy and thereby
reduce the risk from an invasive procedure in a signiﬁcant
number of patients, whilst also providing the required
information for OAV treatment decisions [20–22]. A further
beneﬁt with this approach is evident in subgroup analysis of
males in our study with ALT 20–30IU/L. There were two
male HBeAg+ and three male HBeAg− patients with ALT
between 20–30IU/L who had moderate/severe liver ﬁbrosis
on biopsy. These individuals fall within the normal range by
the Prati criteria and, therefore, would have been missed if
the Prati criteria alone was used as an indication for liver
biopsy.
A major limitation of this study is based on its cross-
sectional design. There will be ﬂuctuations in serum ALT
and HBV DNA missed in cross-sectional analysis and
patient misclassiﬁed as immune tolerant or inactive carriers.
If patients were followed longitudinally with serial blood
tests including HBV viral load and LFTs, then appropriate
classiﬁcation would be achieved. Hence, the standard of care
should be serial blood tests to appropriately classify patients
as long as the time delay does not result in progression in
liver disease or hepatic decompensation [13].
This study shows a correlation between serum ALT and
necroinﬂammatory score as would be expected (in cross-
sectional analysis) as inﬂammation is immediately reﬂected;
however,ﬁbrosistakesmuchlongertoestablish,henceserum
ALT bears no relation to liver ﬁbrosis in the study.
Inconclusion,HBVinfectionisachronic,dynamicinfec-
tion that evolves over many years with both viral and host
factors determining disease activity [2]. This study indicates
that HBeAg status, age, ethnic origin with longitudinal
assessment of LFTs, and viral load should be studied in
patients with “normal ALT” at the upper end of normal
range (ALT 20–40IU/L) to appropriately classify patients
and identify patients for liver ﬁbrosis assessment to inform
treatment decisions.
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